Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 2/20 | 0.36 |
| ▸ | JAK1 | P23458 | 2/20 | 0.36 |
| ▸ | TYK2 | P29597 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | CFB | P00751 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | SPHK1 | Q9NYA1 | 5/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | SPHK2 | Q9NRA0 | 5/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | TACR2 | P21452 | 1/20 | 0.32 |
| ▸ | TACR1 | P25103 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9521804 | 0.87 | GBA1 (0.44) | GBA1JAK2JAK1TYK2ALDH1A1 | |
| SCHEMBL25686606 | 0.84 | GBA1 (0.40) | GBA1JAK2JAK1TYK2ALDH1A1 | |
| SCHEMBL25686459 | 0.82 | GBA1 (0.39) | GBA1JAK2JAK1TYK2ALDH1A1 | |
| SCHEMBL25686622 | 0.81 | CHRM5 (0.48) | GBA1JAK2JAK1TYK2ALDH1A1 | |
| SCHEMBL14045602 | 0.81 | POLB (0.45) | GBA1JAK2JAK1TYK2SPHK1 | |
| SCHEMBL19616665 | 0.81 | POLB (0.45) | GBA1JAK2JAK1TYK2SPHK1 | |
| SCHEMBL8587272 | 0.81 | POLB (0.45) | GBA1JAK2JAK1TYK2SPHK1 | |
| SCHEMBL23206200 | 0.80 | HDAC8 (0.43) | HDAC8HDAC6HDAC1 | |
| SCHEMBL16317627 | 0.78 | HDAC8 (0.42) | GBA1ALDH1A1KDM4EHDAC8HDAC6 | |
| SCHEMBL25686507 | 0.78 | GBA1 (0.36) | GBA1JAK2JAK1TYK2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230174486-A1 | NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF | ALECTOS THERAPEUTICS INC. (CA) | 2023-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230174486-A1 | NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF | GBA1, GBA2, GAA | GBA1 1/4885JAK2 4274/4885JAK1 4728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.